New Insights in Hematologic Malignancies and Disorders: Independent Conference Coverage of the 2019 ASH Annual Meeting
  • CME

December 7-10, 2019; Orlando, Florida
Review the most clinically relevant data in leukemias, lymphomas, MDS, MPNs, multiple myeloma, and nonmalignant hematologic disorders presented at the 2019 ASH Annual Meeting.
Hanny Al-Samkari, MD
Rami S. Komrokji, MD
Sagar Lonial, MD
Jeff P. Sharman, MD
Sujit Sheth, MD
Eunice S. Wang, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: March 17, 2020 Expiration: March 16, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with hematologic malignancies and disorders
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of hematologic malignancies and disorders
  • Discuss new data on novel agents and therapeutic approaches for patients with hematologic malignancies and disorders

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Jeff P. Sharman, MD

Medical Director
Hematology Research
US Oncology Research
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Pharmacyclics, and Sunesis.
Hanny Al-Samkari, MD

Instructor
Department of Medicine
Harvard Medical School
Attending Hematologist and Clinical Investigator
Department of Hematology/Oncoology
Massachusetts General Hospital
Boston, Massachusetts

Hanny Al-Samkari, MD, has disclosed that he has received funds for research support from Agios, Amgen, and Dova and consulting fees from Agios, Dova, and Moderna.
Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Acceleron and Celgene and funds for research support from ApoPharma, Celgene, CRISPR/Vertex, La Jolla, Novartis, and Terumo.
Eunice S. Wang, MD

Professor, Oncology
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, Pfizer, and Stemline and fees for non-CME/CE services from Pfizer and Stemline.
Rami S. Komrokji, MD

Senior Member, Vice Chair
Malignant Hematology
Section Head
Leukemia and MDS
H. Lee Moffitt Cancer Center & Research Institute
Professor
Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from Celgene, Daiichi Sankyo, Jazz, Novartis, and Pfizer.
Sagar Lonial, MD

Professor and Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck, Novartis, and Takeda and funds for research support from Celgene, Janssen, and Takeda.

Staff

Bing-e Xu, PhD

Scientific Director

Bing-E Xu, PhD, has no relevant conflicts of interest to report.
Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Ryan P. Topping, PhD

Scientific Director

Ryan Topping, PhD, has no relevant conflicts of interest to report.
Kristen Rosenthal, PhD

Senior Scientific Director

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa, PhD, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

The Annenberg planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with hematologic malignancies and disorders.

Goal

The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies and disorders.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 17, 2020, through March 16, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

CCO printable treatment algorithm and toxicity management table to help optimize care of your patients with follicular lymphoma

Emily Bucholtz Headshot Emily Bucholtz, RPh Nichole Fisher Headshot Nichole Fisher, RN, BSN Released: September 30, 2020

Jacob D. Soumerai, MD, on how managing patients with CLL has evolved over the first 6 months of the COVID-19 pandemic, from Clinical Care Options (CCO)

person default Jacob D. Soumerai, MD Released: September 30, 2020

Commentary from David Marks, MD, PhD, on considerations for using blinatumomab vs inotuzumab ozogamicin in the treatment of relapsed/refractory ALL, from CCO

Released: September 30, 2020

Expert commentary from Danielle M. Brander, MD, on the implications of MRD evaluation in patients with CLL, as reported by Clinical Care Options (CCO)

Danielle Brander, MD Released: September 29, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue